Neural tube defects
Citation, DOI, disclosures and article data
At the time the article was created Mohd Imran had no recorded disclosures.View Mohd Imran's current disclosures
The neural tube comprises a bundle of nerve sheath which closes to form brain caudally and spinal cord rostrally. The closure should occur at around the 28th day of conception failing which the brain or spinal cord does not form properly.
Numerous types of neural tube defect are recognized including 5,6:
Neural tube defects affect approximately >1-11 out of 1000 pregnancies 4-6.
Folic acid deficiency is one of the leading causes of anencephaly. By supplementing with folic acid in early pregnancy, this defect can be prevented. It is more prevalent in developing countries and in mothers of low socioeconomic status.
maternal obesity 7
anti-epileptic use in pregnancy 8
elevated maternal serum alpha-fetoprotein (MSAFP) levels
elevated amniotic fluid acetylcholinesterase (AChE) levels: in an open neural tube defect 3
These are different for each entity and best discussed under each subtype.
Most neural tube defects can be diagnosed by one of the following tests:
maternal serum alpha-fetoprotein (MSAFP): a screening test performed in the pregnant woman serum during 16-18 weeks of pregnancy (elevated)
amniocentesis: invasive procedure, performed during 15 weeks of pregnancy
Treatment and prognosis
Both the management and prognosis is heavily dependent on the type of neural tube defect. The risk for a subsequent pregnancy is thought to be ~5-10%.
- 1. Gregory Bock, Joan Marsh. Neural Tube Defects. (1994) ISBN: 0471941727 - Google Books
- 2. Eberhard Merz. Ultrasound in Obstetrics and Gynecology. (2005) ISBN: 9781588901477 - Google Books
- 3. Wald N, Cuckle H, Nanchahal K. Amniotic Fluid Acetylcholinesterase Measurement in the Prenatal Diagnosis of Open Neural Tube Defects. Second Report of the Collaborative Acetylcholinesterase Study. Prenat Diagn. 1989;9(12):813-29. doi:10.1002/pd.1970091202 - Pubmed
- 4. Salih M, Murshid W, Seidahmed M. Epidemiology, Prenatal Management, and Prevention of Neural Tube Defects. Saudi Med J. 2014;35 Suppl 1(Suppl 1):S15-28. PMC4362104 - Pubmed
- 5. Copp A, Stanier P, Greene N. Neural Tube Defects: Recent Advances, Unsolved Questions, and Controversies. Lancet Neurol. 2013;12(8):799-810. doi:10.1016/S1474-4422(13)70110-8 - Pubmed
- 6. McDonnell R, Delany V, O'Mahony M, Mullaney C, Lee B, Turner M. Neural Tube Defects in the Republic of Ireland in 2009-11. J Public Health (Oxf). 2015;37(1):57-63. doi:10.1093/pubmed/fdu016 - Pubmed
- 7. Huang H, Chen H, Feng L. Maternal Obesity and the Risk of Neural Tube Defects in Offspring: A Meta-Analysis. Obes Res Clin Pract. 2017;11(2):188-97. doi:10.1016/j.orcp.2016.04.005 - Pubmed
- 8. Egen-Lappe V & Hasford J. Drug Prescription in Pregnancy: Analysis of a Large Statutory Sickness Fund Population. Eur J Clin Pharmacol. 2004;60(9):659-66. doi:10.1007/s00228-004-0817-1 - Pubmed
- 9. Sepúlveda-González G, Arroyo-Lemarroy T, Basurto D et al. Intracranial Translucency, Its Use as a Potential First Trimester Ultrasound Marker for Screening of Neural Tube Defects. Diagnostics (Basel). 2020;10(11):986. doi:10.3390/diagnostics10110986 - Pubmed